AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01267227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pterostilbene 50 mg twice daily
Description: Pterostilbene 50 mg twice by mouth daily for 6 to 8 weeks
Study NCT04088461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850 mg twice daily plus lifestyle modifications program
Study NCT00279708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Placebo vs. Atorvastatin
Study NCT01267227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo by mouth twice daily for 6 to 8 weeks
Study NCT01267227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grape Extract
Description: Grape extract 100 mg twice daily for 6-8 weeks
Study NCT01267227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pterostilbene 125 mg twice daily
Description: Pterostilbene 125 mg twice daily for 6-8 weeks
Study NCT03818867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insertion of cervical cerclage
Description: insertion of a stitch around the neck of the womb in order to provide extra support.
Study NCT01870921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 90mg/tablet, 1 tablet bid
Study NCT04460092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5-mm 32-gauge Insulin needles in the first three days of Intervention
Description: 32-gauge needles with a length of 5mm to inject insulin in first three days
Study NCT04460092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8-mm 32-gauge Insulin needles in the first three days of Intervention
Description: 32-gauge needles with a length of 8mm to inject insulin in first three days
Study NCT04460092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5-mm 32-gauge Insulin needles in the last three days of Intervention
Description: 32-gauge needles with a length of 5mm to inject insulin in second three days
Study NCT04460092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8-mm 32-gauge Insulin needles in the last three days of Intervention
Description: 32-gauge needles with a length of 8mm to inject insulin in second three days
Study NCT01162993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (≥50% relief of pain intensity on a weighted numeric rating scale (NRS) or a score of ≥6 on a seven-point Likert scale (1=very much worse; 7=very much improved) of the PGIC scale for pain and sleep) a definite spinal cord system will be implanted.
Study NCT00279708 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo: Sham Therapy in an oral tablet formulation
Study NCT01741259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperidine
Study NCT04824573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Inspiratory Muscle Training (IMT) was performed with Powerbreathe Classic-Light Resistance device. To determine the intensity of the training, MIP values were measured with the help of the respiratory pressure meter-RP Check (MD Diagnostics Ltd. RP Check MIP \& MEP) device before each training. The pressure corresponding to 50 percent of the MIP value in the Powerbreathe device was determined as training workload. It was applied two days a week for four weeks, with five-set and five repetitions, for 20 minutes with 30 seconds rest in between. This inspiratory muscle training program has previously been used by several studies to improve respiratory muscle strength.
Study NCT04824573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: In the manual diaphragm release technique; While the participant was breathing in, the physiotherapist raised his hand slowly to accompany the rising movement of the ribs and deepened the contact during exhalation. The maneuver was performed in two sets of 10 deep breaths.~In thoracic mobilization application; The physiotherapist, standing behind the participant, wrapped the crossed arms from his right upper arm with his left hand and performed stretching, extension, lateral flexion, and thoracic rotation with his right hand.~In HVLA thoracic manipulation; the physiotherapist, with the support hand on the participant's elbows, applied HVLA thrust in the posterior-anterior and inferior-superior directions with the help of his body while the manipulating hand was on the transverse processes.~For cervical joint mobilization; the physiotherapist was applied using the right hand in flexion, extension, right-left rotation, and lateral flexion directions.
Study NCT04256135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan mobilization
Description: Mobilization will be performed while the patient actively performs knee flexion and/or extension depending on the patient's painful or limited movements. Three series of ten repetitions will be performed.
Study NCT04256135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AP Maitland mobilization
Description: The joint mobilization, will be carried out in the knee with both hands, with displacement of the tibia from the front to the back of the femur in an oscillatory way without pain, will be carried out in blocks of 2 minutes with rests of 30 seconds with a duration of about 6 minutes.
Study NCT03675048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioGaia Protectis drops
Description: food supplement containing the patented lactic acid bacterium Lactobacillus reuteri Protectis®/™ (L. reuteri DSM 17938).
Study NCT03675048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains same excipients as study drug, without the active ingredient L. Reuteri.
Study NCT04276350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture sessions - 2-3 times/week, each session lasting 1 hour, over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling)
Study NCT04276350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Therapy
Description: Best Medical Therapy - 3 biofeedback sessions over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling), where subjects learn and practice the exercises daily
Study NCT03093805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcipotriene
Description: Topical vitamin D cream will be applied to affected areas of the skin.
Study NCT05236309 — intervention group
Intervention type: DRUG
Intervention: Jing-Guan-Fang(JGF) : Chinese herbal decoction
Description: Use 100ml JGF decoction per day as a preventive measure for patients with COVID-19.
Study NCT01045226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Proton Beam Radiation Therapy
Study NCT01045226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life assessment
Description: Quality of Life Assessment
Study NCT01045226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Questionnaire Administration
Study NCT02210585 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: 12 weeks : 5 sessions per week (1 supervised session at home every month)~92 weeks : spontaneous training (supervised by phone every month)
Study NCT02210585 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation
Description: 12 weeks : 5 sessions per week (1 supervised session at home every month)~92 weeks : spontaneous training (supervised by phone every month)
Study NCT04708197 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: rTMS (repetitive transcranial magnetic stimulation )
Description: applying high frequency TMS over the damaged hemisphere in chronic post stroke aphasic patients
Study NCT03082794 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NCD
Description: Negative Calorie Diet
Study NCT03082794 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LCD
Description: Low Calorie Diet
Study NCT01464320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-614
Description: Active
Study NCT01464320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo
Study NCT02262728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir 150 milligram (mg) capsule orally once daily for 12 weeks
Study NCT02262728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Daclatasvir 60 mg tablet orally once daily for 12 weeks
Study NCT02262728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet orally once daily for 12 weeks
Study NCT04555135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoVigilant Software
Description: While using this device, colonoscopy will continue to be performed in the standard manner as is done without the use of this device. The video signal from the colonoscope will be fed into a computer running the EndoVigilant software in addition to the standard video output to the procedure monitor. The gastroenterologist performing the procedure will therefore be able to observe a standard colonoscopy video on the primary monitor and the augmented video on the second monitor. The gastroenterologist may rely on the second monitor (with augmented video generated from EndoVigilant software) for polyp detection, but the standard procedure monitor with the original feed will always be operational and available for maneuvers such as fast insertion, polypectomy etc.
Study NCT01873989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone replacement
Study NCT01873989 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist control
Study NCT02483234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab
Study NCT01236196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone cognitive behavior therapy
Description: Cognitive behavior therapy aimed at teaching pain coping skills was conducted by telephone (12 sessions over a 6-month period).
Study NCT01236196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone pain education
Description: Participants received information on the management of chronic pain during 12 telephone sessions conducted over a 6-month period).
Study NCT03109275 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Single complete MRI intervention
Description: MRI examination will comprise conventional T1 and FLAIR sequences, and advanced sequences such as rs-fMRI and High angular resolution MRI (HARDI).
Study NCT03109275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single complete MRI intervention
Description: MRI examination will comprise conventional T1 and FLAIR sequences, and advanced sequences such as rs-fMRI and High angular resolution MRI (HARDI).
Study NCT02150122 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Study NCT02132000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: toremifene or tamoxifen
Study NCT02132000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toremifene or tamoxifen
Study NCT04768036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMPROVE DD VTE Tool
Description: Universal SMART on FHIR platform-based EHR-embedded IMPROVE VTE CPR with electronic order entry incorporated into required admission and discharge EHR workflow.
Study NCT01117818 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: active: AFFITOPE AD02
Description: vaccination
Study NCT01117818 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: control: Placebo
Description: vaccination
Study NCT02258282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Study NCT02258282 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control
Study NCT02331446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention
Study NCT00484302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy with motivational interviewing
Description: Individual and group therapy, education of family and case-manager.
Study NCT00484302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-manualized standard treatment
Description: Treatment by case-manager
Study NCT00484302 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-manualized standard treatment
Description: Treatment by case-manager
Study NCT02302105 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IGRT
Description: Image Guided RT to the prostate
Study NCT02302105 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IGRT
Description: Image Guided RT to the prostate
Study NCT03380923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity
Description: Exercise prescription intensity is moderate
Study NCT03380923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity
Description: Exercise prescription intensity is high
Study NCT02358694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Serum-Derived Bovine Immunoglobulin
Description: Patients who weigh less than 40 Kg will receive Serum Derived Bovine Immunoglobulin -5 g daily (2.5 g PO BID) and patients who weigh 40 Kg or more will receive Serum Derived Bovine Immunoglobulin- 10 g daily (5 g PO BID)
Study NCT02358694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo packets will be supplied and will appear identical to SBI with respect to volume, appearance and taste.~Patients who weigh less than 40 Kg will take one-half packet BID (2.5 g BID) Patients who weigh 40 Kg or more will take one packet BID (5 g PO BID).
Study NCT04491630 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Hypnosis (SH)
Description: Participants assigned to this condition will listen to a 20-minute recording with instructions of SH adapted from one of our team member's proposed model. First, the audio recording will introduce and orient the participant to SH. Then instruction in SH will be provided, including: (a) how to self-induce a hypnotic induction; (b) specific self-suggestions for comfort and ability to manage intense sensations; and (c) post-hypnotic suggestions that the participant will be easily able to use these hypnotic strategies on their own at a later time (i.e., in this case, during the Cold Pressor Arm Wrap procedures that will follow).~A second 5-minute audio recording with instructions to guide the participant in SH will be provided during the second cycle of Cold Pressor Arm Wrap (CPAW).
Study NCT04491630 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation (MM)
Description: Participants in the MM condition will listen to a 20-minutes recording with instructions in the use and application of Vipassana MM, adapted from the manual developed by one of our team members. First, the audio recording will focus on introducing the idea of attention to their breath, and of non-judgmental monitoring and acceptance of the all events and stimuli. Then a guided MM (body scan) experience will be provided.~A second 5-minute audio recording with instructions to facilitate the MM (body scan) experience taught in the first audio recording will be provided during the second cycle of CPAW.
Study NCT04491630 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Christian Prayer (CP)
Description: Participants in this condition will listen to a 20-minute recording with CP instructions. These instructions will be adapted from the existing on-line biblical meditations from the Society of Jesus (www.passo-a-rezar.net). First, the recording will introduce and orient the participant to CP. Then, a text of the Bible will be read twice, followed by a brief suggestion of prayer.~A second 5-minute audio recording with instructions to facilitate the CP experience taught in the first audio recording, including the recording of a text of the Bible followed by a brief suggestion of meditation and relaxing music, will be provided during the second cycle of CPAW.
Study NCT04906434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60mg ABSK-011capsule
Description: Three 20mg capsules,QD for oral administration
Study NCT04906434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120mg ABSK-011capsule
Description: One 20mg capsule and one 100mg capsule,QD for oral administration
Study NCT04906434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 180mg ABSK-011capsule
Description: One 100mg capsule and four 20mg capsules,QD for oral administration
Study NCT04906434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 240mg ABSK-011capsule
Description: Two 100mg capsules and two 20mg capsules,QD for oral administration
Study NCT04906434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 320 mg ABSK-011capsule
Description: Three 100mg capsule and one 20mg capsule,QD for oral administration
Study NCT04906434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400mg ABSK-011capsule
Description: Four 100mg capsules,QD for oral administration
Study NCT00529386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: 300 units
Study NCT04285190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T89
Description: The subjects in the T89 treatment group will receive 30 pills of T89 orally, bid., for 10 days, except a standard background treatment (antiviral drug + antibacterial + oxygen therapy+ Traditional Chinese Medicine decoction). The subjects in the blank control group will only receive a standard background treatment.
Study NCT03370328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peppermint oil
Description: The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
Study NCT03370328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ginger oil
Description: The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
Study NCT03127397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Praise message phone call
Description: Praise message phone calls after each completed ART appointment, up to two calls per month.
Study NCT01500824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib, 250 mg BID, will be administered orally at approximately the same time each day on a continuous daily dosing schedule
Study NCT01663259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Before Radiotherapy patients you will receive a single loading dose of cetuximab. Patients will also have two additional biopsies before and after cetuximab to determine how the tumor is affected. A Cetuximab infusion will also be delivered once a week during radiotherapy.Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week. In order to evaluate swallowing problems from radiotherapy, patients will undergo an evaluation of swallowing by videofluoroscopy (VF). Quality of Life questionnaires will be given before therapy and periodically up to 36 months after therapy. In order to assess if the tumor was completely eradicated, CT-PET scan will be performed 3 months after the completion of therapy.
Study NCT01663259 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week.
Study NCT04688840 — intervention group
Intervention type: PROCEDURE
Intervention: hip arthropalsty
Description: follow up of patients with primary hip arthroplasty with at least one year follow up electronically and by routine method
Study NCT04425499 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Learning running subcuticular sutures on the Gamified Educational Network
Description: Each arm will have 15 participants who will learn how to perform running subcuticular sutures through videos on GEN.
Study NCT04425499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Learning running subcuticular sutures on the Gamified Educational Network
Description: Each arm will have 15 participants who will learn how to perform running subcuticular sutures through videos on GEN.